A deep-tech platform company at the intersection of microfluidics, automation, and AI — with granted IP, a CRO validation partnership, and a clear path to revenue.
The FDA is phasing out animal-testing requirements for monoclonal antibodies, pushing the industry toward microphysiological systems.
In-silico discovery has exploded the number of candidate targets — but experimental validation has not kept pace, creating a severe bottleneck.
China and APAC are outpacing the world in lab automation and robotics to meet surging biotech demand.
Nearly half of all pharma R&D spend sits in discovery and preclinical — the stages before a molecule ever reaches a patient. That is precisely where OncoMiMIC operates, and precisely where a wrong answer is cheapest to catch.
Hit-to-Lead and Lead Optimization together account for $195M of out-of-pocket cost per successful new molecular entity. Compress the cost and time of those two stages by 50–60% and roughly $400M is freed per NME.
The asymmetry is what matters. A candidate killed in Lead Optimization costs a fraction of one killed in Phase II — and every day of delay in development costs an estimated $500K.
OncoMiMIC's impact zone is the four stages before the clinic. More physiologically relevant data, five or more readouts per run, arriving 5–20× faster.
Core compartmentalized microfluidics IP, licensed from A*STAR, with our CSO as named inventor. Peer-reviewed foundation in Bioengineering & Translational Medicine.
Injection-molded chips at scale, in an ISO 9001 facility, with a founder who has run 1,000 wafers a month. Most MPS competitors hand-cast in PDMS.
Competitors sell a chip or an instrument. We integrate all four subsystems — and sell the capability itself as services while the platform matures.
~$50K SGD in-kind services for the proof-of-concept project. All IP developed belongs to the company.
~6 months of funding for microfluidic scale-up and MVP low-plex chip development.
A*STAR GAP Fund, AME YIRG and other schemes — 5+ years of core platform development already funded.
We are raising a pre-seed round. Get in touch and a member of the founding team will follow up personally within two business days.
Request the deck →